Gynecology

Developed Formulas
Benefits
  • Supports the treatment and prevention of cystitis
  • Counteracts intestinal permeability
  • Selectively inhibits Escherichia coli
Gynecology
Ready to market
Gynecology
Microbac
Gynecology
In vitro test
Gynecology
Hydrosoluble powder
Gynecology
Allergen Free
Gynecology
Real time stability
Gynecology
Orosoluble
Components

Lacticaseibacillus rhamnosus LR06 (DSM 21981)
Cranberry (Vaccinium macrocarpon Aiton), fruit, d.j.
Proanthocyanidins (PACs)

Label Claim

Food supplement with probiotic strains.

Effective nutraceutical combination


Biotin
EFSA Claim: contributes to the mantainance of normal mucosa

Scientific Rationale
In vitro studies

With approximately 150 million people affected globally each year, urinary tract infections (UTIs) rank as one of the most prevalent bacterial infections [1-3]. UTIs are attributed to a broad spectrum of pathogens, predominantly involving uropathogenic Escherichia coli (UPEC) [2,3]. PROBIAL® CYS is a supplement devised with a dual-action strategy to combat and prevent UTIs, thanks to:

  • Lacticaseibacillus rhamnosus LR06: Demonstrated in in vitro studies, LR06 has shown a strong and selective inhibition of E. coli growth, including the pathogenic serotype O157:H7 [4]. It also plays a role in restoring membrane integrity following damage induced by pro-inflammatory stimuli, aiding in countering leaky gut syndrome [5].

  • Cranberry d.e (dry extract): Notably rich in proanthocyanidins A, its phytocomplex is among the most clinically supported in terms of antimicrobial activity against E. coli [6].

The formulation is available in orosoluble powder, facilitating ease of use even when away from home, as well as in hydrosoluble powder form

Bibliography

1. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001 Mar 1;183 Suppl 1:S1-4. doi: 10.1086/318850. 

2. Flores-Mireles AL, et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015 May;13(5):269-84. doi: 10.1038/nrmicro3432

3. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014 Mar;28(1):1-13. doi: 10.1016/j.idc.2013.09.003

4. Mogna L, et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012 Oct;46 Suppl:S29-32. doi: 10.1097/MCG.0b013e31826852b7

5. Internal Probiotical data

6. Blumberg JB, et al. Cranberries and their bioactive constituents in human health. Adv Nutr. 2013 Nov 6;4(6):618-32. doi: 10.3945/an.113.004473

Associations